Salicylic acid demand in China is bifurcating sharply. On the cosmetic side, the acne-treatment boom is driving growth, but formulators are moving away from plain 2% solutions toward encapsulated or supramolecular versions that release slowly over 12 hours, reducing irritation. This shifts demand toward higher-value, specialty grades rather than commodity material. On the pharmaceutical side, salicylic acid remains a key intermediate for aspirin and other actives, with steady industrial consumption. The industrial market, however, is more cyclical and price-sensitive, as seen historically when overcapacity among nearly 20 domestic producers in the 1990s halved prices. Today, the growth premium is clearly in personal care, where efficacy claims and gentler delivery systems justify higher raw-material costs.
Comments
0